Data by Company within In Vitro & In Vivo Diagnostic Substances Industry
|
|
Marketcap |
Revenues (TTM) |
Net Income (TTM) |
Employees |
Company |
(Millions) |
(Millions) |
(Millions) |
Number |
Idexx Laboratories Inc |
$ 44,504 |
$ 3,660 |
$ 845 |
10,350 |
Oncocyte Corporation |
$ 24,933 |
$ 6 |
$ -77 |
- |
Ortho Clinical Diagnostics Holdings Plc |
$ 8,448 |
- |
$ 54 |
- |
Lantheus Holdings Inc |
$ 3,971 |
$ 1,296 |
$ 327 |
1,000 |
Quidelortho Corp |
$ 3,278 |
$ 3,122 |
$ 13 |
- |
Neogen Corporation |
$ 3,268 |
$ 918 |
$ -27 |
1,700 |
Intellia Therapeutics Inc |
$ 2,426 |
$ 52 |
$ -462 |
- |
Celldex Therapeutics inc |
$ 1,984 |
$ 7 |
$ -141 |
- |
Myriad Genetics Inc |
$ 1,791 |
$ 753 |
$ -263 |
2,700 |
Meridian Bioscience Inc |
$ 1,504 |
$ 339 |
$ 62 |
850 |
Heska Corporation |
$ 1,247 |
$ 255 |
$ -20 |
542 |
Mymd Pharmaceuticals Inc |
$ 128 |
- |
$ -5 |
- |
Achieve Life Sciences Inc |
$ 97 |
- |
$ -36 |
- |
Alpha Teknova Inc |
$ 85 |
$ 36 |
$ -39 |
- |
Trinity Biotech Plc |
$ 73 |
$ 75 |
$ -41 |
569 |
Volitionrx Limited |
$ 68 |
$ 1 |
$ -34 |
- |
Quotient Limited |
$ 39 |
$ 39 |
$ -136 |
- |
Immucell Corp |
$ 39 |
$ 16 |
$ -6 |
- |
Aspira Women s Health Inc |
$ 36 |
$ 9 |
$ -21 |
1,433 |
Arca Biopharma Inc |
$ 25 |
- |
$ -5 |
- |
Lucira Health Inc |
$ 18 |
$ 212 |
$ -143 |
100 |
Nymox Pharmaceutical Corporation |
$ 18 |
$ 0 |
$ -7 |
- |
Biomerica Inc |
$ 15 |
$ 5 |
$ -7 |
- |
Navidea Biopharmaceuticals Inc |
$ 4 |
$ 1 |
$ -1 |
- |
Burzynski Research Institute Inc |
$ 2 |
- |
$ -1 |
- |
Cardio Diagnostics Holdings Inc |
- |
$ 6 |
$ -11 |
- |
In Vitro & In Vivo Diagnostic Substances Industry |
$ 98,000 |
$ 10,799 |
$ -184 |
19,244 |
Recent News from In Vitro & In Vivo Diagnostic Substances Industry |
Clinical Study
Intellia Therapeutics, a renowned clinical-stage gene editing company, has recently commenced the global pivotal, Phase 3 MAGNITUDE trial of their investigational therapy, NTLA-2001. This single-dose, in vivo CRISPR-based treatment aims to inactivate the TTR gene, thereby preventing the production of TTR protein in patients with transthyretin (ATTR) amylo...
|
|
Product Service News
Trinity Biotech Regains Nasdaq Compliance Following Minimum Closing Bid Price RuleDUBLIN, Ireland - Trinity Biotech Plc. (NASDAQ: TRIB) announced today that it has successfully regained compliance with the minimum closing bid price requirement set by The Nasdaq Stock Market. The company had received a formal notification from Nasdaq regarding its complian...
|
|
Announcement
In recent news, the highly reputable law firm, Rosen Law Firm, has urged investors of QuidelOrtho Corporation (NASDAQ: QDEL) to participate in an ongoing securities class action investigation. The investigation aims to determine if QuidelOrtho has potentially provided misleading business information, which may have caused significant harm to shareholders....
|
|
Product Service News
Lantheus Announces FDA Approval of DEFINITY (Perflutren Lipid Microsphere) for Pediatric Patients; Solidifies its Position as the Leading Ultrasound Enhancing Agent for Suboptimal Echocardiograms in the U.S.In a recent press release, Lantheus, a global leader in diagnostic imaging, announced the much-anticipated approval of DEFINITY (Perflutren Lipid Micr...
|
|
Announcement
Investigation Underway for Potential Securities Claims against QuidelOrtho CorporationIn the rapidly evolving world of investments, investors rely heavily on accurate and reliable information when making decisions about where to allocate their funds. With this in mind, it is concerning to hear allegations that QuidelOrtho Corporation may have issued misl...
|
|
Stock Market Announcement
Celldex Therapeutics Announces Pricing of Upsized Public Offering, Expected to Raise $400.4 Million Celldex Therapeutics, Inc. (Celldex), a biopharmaceutical company focused on developing targeted immunotherapies for the treatment of cancer and other diseases, made a significant announcement today regarding the pricing of an upsized underwritten publi...
|
|
Product Service News
In a significant development, Achieve Life Sciences recently announced that it has successfully reached an agreement with the U.S. Food and Drug Administration (FDA) regarding the requirements for long-term exposure data on Cytisinicline, a promising compound for smoking cessation. The agreement marks a major step forward for Achieve Life Sciences as it m...
|
|
Management Announcement
Achieve Life Sciences Announces $124.2 Million Offering Amidst Accumulating Losses and Challenging Competition Achieve Life Sciences Inc has made headlines once again, this time with its recent pricing of a registered direct offering and concurrent private placement, aiming to raise up to $124.2 million. This considerable financing effort involves a...
|
|
Myriad Genetics Inc
r/>Myriad Genetics Inc., a leading molecular diagnostics company, recently announced its participation in an innovative clinical trial that aims to transform the way we monitor minimal residual disease (MRD) across different types of cancer. This collaboration with the National Cancer Center Hospital East in Japan marks a significant milestone in cancer r...
|
|
Shares
Hampton, N.J., Feb. 28, 2024 - Celldex Therapeutics, Inc. (Nasdaq: CLDX) has recently announced its proposal to offer and sell shares of common stock in an underwritten public offering, with an added option for underwriters to purchase additional shares. This move comes in line with the company's commitment to continue clinical and preclinical develo...
|
|
|
|
|
|